SK pharmteco has entered into a new strategic collaboration with the Orphan Therapeutics Accelerator (OTXL), a non-profit biotechnology organization focused on advancing stalled rare disease treatments, in an effort to accelerate the development of promising therapies for patients with unmet medical needs.
The agreement strengthens SK pharmteco’s commitment to supporting rare disease drug development through its Rare Disease Advancement Initiative, a program designed to help bring innovative therapies to patients more quickly while providing flexible commercial support for developers facing limited resources and complex development challenges.
Under the partnership, SK pharmteco will act as a preferred technical partner for OTXL, offering manufacturing and development expertise to help move rare disease programs toward key clinical and commercial milestones. The collaboration aims to address one of the most significant hurdles in rare disease drug development: access to reliable and scalable manufacturing capabilities.
Joerg Ahlgrimm, Chief Executive Officer of SK pharmteco, said the company is dedicated to helping patients with rare diseases gain access to life-changing treatments through advanced manufacturing support.
“Rare disease programs often operate under compressed timelines and unique resource constraints,” Ahlgrimm said. “By combining our specialized manufacturing capabilities and technical expertise with OTXL’s programs, we can help accelerate the development and delivery of critical therapies while strengthening our position as a leading contract development and manufacturing organization for rare diseases.”
As part of the arrangement, SK pharmteco will provide prioritized access and preferential pricing for up to two therapeutic programs each year. This support is expected to help developers overcome common barriers related to manufacturing costs, capacity, and technical complexity.
The collaboration covers several key development services, including process development, analytical development, and Good Manufacturing Practice (GMP) manufacturing with quality control release testing. Process development services will focus on optimizing and scaling manufacturing protocols for advanced therapeutic modalities, while analytical development will ensure the creation of precise testing methods to support product characterization and safety assessments. GMP manufacturing services will help ensure regulatory compliance and product quality for clinical-stage programs.
OTXL Founder and Chief Executive Officer Craig Martin emphasized the importance of reducing manufacturing risks for rare disease therapies. He noted that uncertainty around manufacturing access, cost, and long-term continuity can often prevent promising treatments from reaching patients.
According to Martin, building a network of trusted partners capable of supporting development through commercialization is essential for creating sustainable pathways for rare disease programs. He added that SK pharmteco’s global technical expertise and willingness to structure support around the realities of rare disease development make the company a valuable addition to OTXL’s growing ecosystem.
The partnership reflects a broader industry effort to address challenges in rare disease drug development, where limited patient populations and high development costs often make it difficult for innovative therapies to progress. By combining technical expertise, manufacturing infrastructure, and collaborative support, SK pharmteco and OTXL aim to improve the chances of bringing new treatments to patients who currently have few or no therapeutic options.